ReviewAdvances in experimental medicine and biology2026
Regulation of the Anti-termination RNA Transcription Complex by Lon-Mediated Lambda N Degradation.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lambda N protein (λN) is an intrinsically unstructured protein functioning to mediate anti-termination transcription of lambda phage RNA during the infection of Escherichia coli (E. coli) host by interacting with the host's macromolecular transcription machinery. In E. coli host, λN is primarily turned over by the ATP-dependent protease Lon. While it has been demonstrated that Escherichia coli Lon (ELon) readily degrades purified λN in vitro, it is unclear how ELon degrades λN in the RNA anti-termination transcription complex. The N-dependent anti-termination transcription mechanism of Escherichia coli RNA polymerase (ERNAP) and the quality control functions of Lon have been extensively studied and reviewed in literature. By contrast, very little is known about Lon's function as a regulatory protease. Herein, we provide a survey of literature and newfound evidence showing how ELon regulates anti-termination RNA transcription assemblies by using λN as a substrate. Elucidating how a substrate interacts with the various components in the assembly (ERNAP versus ELon) can dictate whether anti-termination transcription or degradation occurs.
Indexed as
Identifiers
42334542What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.